Recent Decline in Risk for CRC Recurrence Seen in Stage I to III Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 28, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Nov. 28, 2023 -- From 2004 to 2019, the risk for recurrence of colorectal cancer (CRC) decreased in patients with stages I to III disease, according to a study published online Nov. 16 in JAMA Oncology to coincide with the annual meeting of the Danish Surgical Society, held from Nov. 16 to 17 in Copenhagen.

Jesper Nors, M.D., from Aarhus University Hospital in Denmark, and colleagues examined the rates of recurrence and time to recurrence within five years of surgery with curative intent in a cohort of 34,166 patients with Union for International Cancer Control (UICC) stages I to III CRC who underwent primary surgery from Jan. 1, 2004, to Dec. 31, 2019. The association between calendar period of primary surgery (2004 to 2008, 2009 to 2013, and 2014 to 2019) and recurrence risk was examined.

The researchers found that 7,027 participants developed recurrence within five years after the primary surgery. During the three calendar periods, the five-year cumulative incidence function of recurrence decreased from 16.3 to 6.8 percent, 21.9 to 11.6 percent, and 35.3 to 24.6 percent for UICC stage I, II, and III colon cancer, respectively. The corresponding decreases for rectal cancer were from 19.9 to 9.5 percent, 25.8 to 18.4 percent, and 38.7 to 28.8 percent. Compared with those with stage I disease, patients with stage III disease had a shorter time from surgery to recurrence. Lower stage-adjusted risks for recurrence were seen for cancers detected versus not detected through screening (subdistribution hazard ratio, 0.81).

"We believe that the risk of CRC recurrence has become so low in selected patient groups that further research on personalized surveillance protocols is indicated," the authors write.

One author disclosed ties to industry.

Abstract/Full Text

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-11-29 02:32

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords